AGENUS INC (AGEN) Stock Price, Forecast & Analysis
NASDAQ:AGEN • US00847G8042
AGEN Key Statistics, Chart & Performance
The current stock price of AGEN is 2.92 USD. In the past month the price decreased by -20.65%. In the past year, price decreased by -16.81%.
AGEN Technical Analysis
AGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AGEN. AGEN may be in some trouble as it scores bad on both profitability and health.
AGEN Financial Highlights
Over the last trailing twelve months AGEN reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 81.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AGEN Forecast & Estimates
9 analysts have analysed AGEN and the average price target is 12.58 USD. This implies a price increase of 330.82% is expected in the next year compared to the current price of 2.92.
For the next year, analysts expect an EPS growth of 91.44% and a revenue growth 0.26% for AGEN
AGEN Ownership
AGEN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AGEN
Company Profile
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Company Info
AGENUS INC
3 Forbes Rd
Lexington MASSACHUSETTS 02421 US
CEO: Garo H. Armen
Employees: 316
Phone: 17816744410
AGENUS INC / AGEN FAQ
Can you describe the business of AGENUS INC?
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Can you provide the latest stock price for AGENUS INC?
The current stock price of AGEN is 2.92 USD. The price increased by 2.46% in the last trading session.
Does AGEN stock pay dividends?
AGEN does not pay a dividend.
How is the ChartMill rating for AGENUS INC?
AGEN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is AGENUS INC (AGEN) stock traded?
AGEN stock is listed on the Nasdaq exchange.
What is the next earnings date for AGEN stock?
AGENUS INC (AGEN) will report earnings on 2026-03-09, after the market close.
What is the outstanding short interest for AGENUS INC?
The outstanding short interest for AGENUS INC (AGEN) is 10.4% of its float.